MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells
出版年份 2018 全文链接
标题
MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells
作者
关键词
-
出版物
Oncogenesis
Volume 7, Issue 9, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-09-06
DOI
10.1038/s41389-018-0078-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- FBW7 -Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors
- (2017) Jingshan Tong et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
- (2017) A N Hata et al. ONCOGENE
- Combined MEK and Pi3’-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo
- (2017) Oussama ElMokh et al. Oncotarget
- FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
- (2016) J Tong et al. ONCOGENE
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma
- (2015) U Heinicke et al. ONCOGENE
- Subcellular localization of PUMA regulates its pro-apoptotic activity in Burkitt’s lymphoma B cells
- (2015) Gorbatchev Ambroise et al. Oncotarget
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
- (2014) D. Chen et al. CLINICAL CANCER RESEARCH
- The Biology and Clinical Development of MEK Inhibitors for Cancer
- (2014) Jason J. Luke et al. DRUGS
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- (2014) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- Mutations of theBRAFgene in human cancer, by Davieset al. (Nature2002; 417: 949-54)
- (2013) G. W. M. Millington CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
- (2013) F. Catalanotti et al. CLINICAL CANCER RESEARCH
- Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells
- (2013) X. Zheng et al. MOLECULAR CANCER THERAPEUTICS
- BIM, PUMA, and the Achilles' Heel of Oncogene Addiction
- (2013) A. Roulston et al. Science Signaling
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice
- (2011) Wei Qiu et al. HEPATOLOGY
- PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice
- (2011) Wei Qiu et al. JOURNAL OF CLINICAL INVESTIGATION
- PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01
- (2010) C. Dudgeon et al. MOLECULAR CANCER THERAPEUTICS
- PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells
- (2009) Q Sun et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now